Pharmaceutical News and Articles

Tolebrutinib Regulatory Submission Accepted for Priority Review in the US for Patients with Multiple Sclerosis

The United Laboratories and Novo Nordisk Announce Exclusive License Agreement for UBT251, a GLP-1/GIP/Glucagon Triple Receptor Agonist

Guangdong, China and Bagsv rd, Denmark, 24 March 2025 The United Laboratories International Holdings Limited (TUL) and Novo Nordisk A S (Novo Nordisk) today ann

FDA Approves Blujepa for Uncomplicated Urinary Tract Infections

The U.S. Food and Drug Administration has approved Blujepa (gepotidacin) for the treatment of uncomplicated urinary tract infections (uUTIs) in adult women (wei

Psychological Prehabilitation Boosts Patients' Postsurgical Outcomes

Psychological prehabilitation may improve four postoperative outcomes reduced length of stay (LOS), pain, anxiety, and depression, according to a review recentl

Aquablation Appears to Be Safe, Effective for Enlarged Prostates

The Aquablation water-based surgical procedure is safe and effective for use with enlarged prostates compared with laser surgery, according to a study presented

High-Riding Patella Seen in ACL Reconstruction, Uninjured Contralateral Knees

In anterior cruciate ligament reconstruction (ACLR) and uninjured contralateral knees, the patella articulates higher on the femoral trochlea due primarily to a

Long-Term Gantenerumab May Slow Decline in Dominantly Inherited Alzheimer Disease

For individuals with dominantly inherited Alzheimer disease (DIAD), long-term treatment with gantenerumab, an anti-amyloid beta antibody, may delay clinical dec

Six Months of Breastfeeding Tied to Lower Odds of Developmental Delays

Exclusive or longer duration of breastfeeding (at least six months) is associated with reduced odds of developmental delays, according to a study published onli

2013 to 2022 Saw Rapid Increase in U.S. Pedestrian, Traffic Death Rates

From 2013 to 2022, the U.S. pedestrian and road traffic death rate increased rapidly compared with a decrease in other high-income countries, according to resea

Novo Nordisk To Pay $2 Billion for New Weight Loss Drug

Novo Nordisk, a Danish pharmaceutical company, has signed a major deal worth up to 2 billion for the rights to a new obesity and diabetes drug, the company anno